Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275

Anti-Cancer Drugs

Volumn 22, Issue 6, 2011, Pages 494-499

  Bangert, Annette ^a   Häcker, Sabine ^a   Cristofanon, Silvia ^b   Debatin, Klaus Michael ^a   Fulda, Simone ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

apoptosis; chemotherapy; glioblastoma; histone deacetylase inhibitor

Indexed keywords

CISPLATIN; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; HISTONE H3; PACLITAXEL; TEMOZOLOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CHEMOSENSITIZATION; DRUG MECHANISM; DRUG POTENTIATION; GLIOBLASTOMA; HISTONE ACETYLATION; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; CISPLATIN; DACARBAZINE; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MICROTUBULES; PYRIDINES;

EID: 79958254773     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834631e0     Document Type: Article

References (21)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60:166-193.
2. Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-466.
3. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25:4798-4811. (Pubitemid 44187627)
4. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87:99-163. (Pubitemid 46209992)
5. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124:511-515.
6. Hanahan D,Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
7. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 2008; 8:132-140. (Pubitemid 351347249)
8. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8:1409-1420.
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-784. (Pubitemid 44348499)
10. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51. (Pubitemid 43054973)
11. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280:125-133.
12. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent. Int J Biochem Cell Biol 2007; 39:1388-1405. (Pubitemid 47031032)
13. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008; 68:6271-6280.
14. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57:3823-3829. (Pubitemid 27381230)
15. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007; 26:186-197. (Pubitemid 46095730)
16. Jordan MA,Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-265.
17. Sarcar B, Kahali S, Chinnaiyan P. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J Neurooncol 99:201-207.
18. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004; 59:1174-1180. (Pubitemid 38834312)
19. Lopez CA, Feng FY, Herman JM, Nyati MK, Lawrence TS, Ljungman M. Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int J Radiat Oncol Biol Phys 2007; 69:214-220. (Pubitemid 47247526)
20. Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci U S A 2006; 103:1587-1592. (Pubitemid 43191209)
21. Eyupoglu IY, Hahnen E, Trankle C, Savaskan NE, Siebzehnrubl FA, Buslei R, et al. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 2006; 5:1248-1255. (Pubitemid 43881317)